Prescribing information

 

A short video explaining how to prepare and administer the Beovu pre-filled syringe.

 
 
Image of syringe and packaging

Beovu is available in a sterile, single-use, prefilled syringe.1,2 Please refer to the syringe for expiry date. More patients in less time with a prefilled syringe versus a standard vial dose method*4

 

*Reference supports the concept of a prefilled syringe treating more patients in less time, but is not specific to Beovu.

Click here to view the Beovu treatment posology for wet AMD

Registration is required to access this resource

 

References

  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  3. Beovu Patient Information leaflet, 2022.
  4. Souied E, et al. Eur J Ophthalmol 2015;25(6):529–534.

 

AMD, age-related macular degeneration; HCP, healthcare professional.

Rate this content: 
No votes yet
UK | May 2022 | 209132
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]